Charles River’s CDMO business slows; Lilly boosts GLP-1 capacity; Teva’s Israel sites 'unaffected'
Endpoints News delved into another week of investor calls to gather key biopharma manufacturing updates. We found that Charles River is looking to increase its manufacturing customers with commercial assets, and Eli Lilly is aiming to further bolster manufacturing for its weight loss drug.
Charles River is looking to improve its CDMO business after this segment’s revenue decreased by 7.3% in the third quarter, down to $175.7 million from $189.6 million reported in the same time last year. In total, the manufacturing division made $596.5 million in the first three quarters of 2023, down from $577.5 million last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.